(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Instructions to Figure out the Various Phases of Cellular breakdown in the lungs - 2Attorney-General to High Court: Gov’t violating draft ruling, risking rule of law
- 3Pick Your Favored kind of soup
- 4Instructions to Distinguish the Wellbeing Dangers Related with 5G Pinnacles
- 5Vote In favor of Your Favored Menial helper Administration
- ‘Raising 10 red flags’: Is Israel’s army exhausted?
- Monetary Strengthening: Assuming Command over Your Cash
- From Fledgling to Master: Self-awareness in a Side interest
- Chief of Staff Zamir warns IDF will collapse due to lack of manpower, raises 'ten red flags'
- Picking the Right Doctor prescribed Medication Inclusion in Senior Protection.
- Starship success, a private moon landing and more: The top 10 spaceflight stories of 2025
- 9 African migrants died in freezing temperatures near Morocco-Algeria border
- The most effective method to Integrate Compact disc Rates into Your Retirement Arranging
- Most loved Seared Chicken: Which Chain Rules?
